Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Head and Neck Surgery, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan.
Acta Otolaryngol. 2020 Dec;140(12):1043-1048. doi: 10.1080/00016489.2020.1807601. Epub 2020 Aug 18.
Significant immune-related adverse events (irAEs) requiring therapy discontinuation sometimes occur. The influence of discontinuation on disease control after an irAE is unclear.
The aim of this study was to investigate whether or not patients continued to show a response or durable disease control even after stopping therapy following an irAE.
The response after nivolumab monotherapy discontinuation was examined for 14 patients in whom therapy was stopped without progression.
The best response was CR in 5 (36%) patients, PR in 8 (57%) patients and SD in 1 (7%) patient. The estimated 1-year overall and progression-free survival rates were 92.9% and 78.6%, respectively. The best response during nivolumab therapy in patients who developed PD was CR in 0 of 5 patients (0%), PR in 3 of 8 patients (38%) and SD in 1 patient (100%). Patients obtaining CR tended to have a lower risk of PD than those with PR or SD.
Patients with CR status may continue to show a response or durable disease control even after stopping therapy due to an irAE.
免疫相关不良事件（irAEs）有时会导致需要停止治疗的严重不良事件。irAE 停药后对疾病控制的影响尚不清楚。
本研究旨在探讨 irAE 后停止治疗是否会导致患者继续出现缓解或持久的疾病控制。
对 14 例无进展性疾病的 irAE 停药患者进行了检查。
5 例（36%）患者的最佳缓解为完全缓解（CR），8 例（57%）患者为部分缓解（PR），1 例（7%）患者为疾病稳定（SD）。估计 1 年总生存率和无进展生存率分别为 92.9%和 78.6%。在发生 PD 的患者中，nivolumab 治疗期间的最佳缓解为 0 例（0%）CR，3 例（38%）PR 和 1 例（100%）SD。获得 CR 的患者发生 PD 的风险低于 PR 或 SD 的患者。
CR 状态的患者即使因 irAE 停止治疗，也可能继续出现缓解或持久的疾病控制。
